In 2022, the prevalence of diagnosed diabetes in the United States among people aged 18 and over amounted to 8.4 percent.

How many people in the United States have diabetes? It was estimated that in 2022, around 24.4 million people in the United States had been diagnosed with diabetes. The number of people living with diabetes has increased over the past few decades, with only five million people living with diabetes in the year 1980. Diabetes in the United States is more common among older adults with around 24 percent of those aged 65 years and older diagnosed with diabetes, compared to 15 percent of those aged 45 to 64 years.

Leading diabetic states

In 2021, the U.S. states with the highest prevalence of diagnosed diabetes were Alabama, Mississippi, and West Virginia, respectively. Just over 17 percent of adults in Alabama had diabetes that year. Roughly 14 percent of adults in Georgia had been diagnosed with diabetes before or during the measured period, putting the state of Georgia in tenth place.

United States US: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 10.790 % in 2017. United States US: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 10.790 % from Dec 2017 (Median) to 2017, with 1 observations. United States US: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

It was estimated that as of 2022 around 24.4 million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the eighth leading cause of death in the United States, accounting for three percent of all deaths.

What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around 53 million men and 44 million women in the United States had prediabetes. However, according to the CDC, around 80 percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are Hawaii, California, and Alaska.

The prevalence of diabetes in the United States As of 2022, around 8.4 percent of adults in the United States had been diagnosed with diabetes, an increase from six percent in the year 2000. Diabetes is much more common among older adults, with almost a quarter of those aged 65 years and older diagnosed with diabetes, compared to just three percent of those aged 18 to 44 years. The states with the highest prevalence of diabetes among adults are Alabama, Mississippi, and West Virginia, while Colorado and Alaska report the lowest rates. In Alabama, around 17 percent of adults have been diagnosed with diabetes.

Diabetes prevalence (% of population ages 20 to 79) in United States was reported at 10.7 % in 2021, according to the World Bank collection of development indicators, compiled from officially recognized sources. United States - Diabetes prevalence (% of population ages 20 to 79) - actual values, historical data, forecasts and projections were sourced from the World Bank on June of 2025.

Around 10.5 percent of the global adult population suffered from diabetes in 2021 - by the year 2045 this number is expected to rise to over 12 percent. Diabetes, or diabetes mellitus, refers to a group of metabolic disorders that result in chronic high blood sugar levels. Diabetes can lead to serious health complications, such as cardiovascular disease, chronic kidney disease, and stroke and is now among the top ten leading causes of death worldwide.

Prevalence
Diabetes is a global problem affecting a variety of countries. China currently has the largest number of diabetics worldwide with some 141 million people suffering from the disease. However, the highest prevalence of diabetes is found among French Polynesia, Mauritius, and Kuwait. Rates of diabetes have increased in many countries in recent years, as have rates of obesity, one of the leading risk factors for the disease.

Outlook
It is predicted that diabetes will continue to be a problem in the future. Africa is expected to see a 134 percent increase in the number of diabetics in the region from 2021 to 2045, while North America and the Caribbean are expected to see an increase of 24 percent. In 2045, China is predicted to be the country with the highest number of diabetics worldwide, with the United States accounting for the fourth highest number.

This dataset contains information on the proportion by age, total number, male and female and sex of adults of adults diagnosed with diabetes, collected from the system of health-related telephone surveys, the Behavioral Risk Factor Surveillance System (BRFSS), conducted in more than 400,000 patients, from 50 states in the US, the District of Columbia and three US territories.

Health, United States is an annual report on trends in health statistics, find more information at http://www.cdc.gov/nchs/hus.htm.

Population-based county-level estimates for diagnosed (DDP), undiagnosed (UDP), and total diabetes prevalence (TDP) were acquired from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (Evaluation 2017). Prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or hemoglobin A1C (HbA1C) levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (Dwyer-Lindgren, Mackenbach et al. 2016). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or A1C status for each BRFSS respondent (Dwyer-Lindgren, Mackenbach et al. 2016). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict the county-level prevalence of each of the diabetes-related outcomes (Dwyer-Lindgren, Mackenbach et al. 2016). Diagnosed diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis, represented as an age-standardized prevalence percentage. Undiagnosed diabetes was defined as proportion of adults (age 20+ years) who have a high FPG or HbA1C but did not report a previous diagnosis of diabetes. Total diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis and/or had a high FPG/HbA1C. The age-standardized diabetes prevalence (%) was used as the outcome. The EQI was constructed for 2000-2005 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that _domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each _domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and _domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, S. Shaikh, D. Lobdell, and R. Sargis. Association between environmental quality and diabetes in the U.S.A.. Journal of Diabetes Investigation. John Wiley & Sons, Inc., Hoboken, NJ, USA, 11(2): 315-324, (2020).

Population-based county-level estimates for prevalence of DC were obtained from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (16). DC prevalence rate was defined as the propor-tion of people within a county who had previously been diagnosed with diabetes (high fasting plasma glu-cose 126 mg/dL, hemoglobin A1c (HbA1c) of 6.5%, or diabetes diagnosis) but do not currently have high fasting plasma glucose or HbA1c for the period 2004-2012. DC prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or HbA1C levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (16). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or HbA1C status for each BRFSS respondent (16). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict county-level prevalence of diabetes-related outcomes, including DC (16). The EQI was constructed for 2006-2010 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). Results are reported as prevalence rate differences (PRD) with 95% confidence intervals (CIs) comparing the highest quintile/worst environmental quality to the lowest quintile/best environmental quality expo-sure metrics. PRDs are representative of the entire period of interest, 2004-2012. Due to availability of DC data and covariate data, not all counties were captured, however, the majority, 3134 of 3142 were utilized in the analysis. This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, K. Price, D. Lobdell, and R. Sargis. Diabetes control is associated with environmental quality in the USA. Endocrine Connections. BioScientifica Ltd., Bristol, UK, 10(9): 1018-1026, (2021).

This forecast represents the prevalence of diabtes among the total population of the United States in 2025, sorted by characteristic. In 2025, the diabetes prevalence for the United States is expected to be 14.9 percent.

This forecast illustrates the number of diabetes type 2 cases in the United States from 2007 to 2020. In 2020, some 28.2 million adults among the U.S. population are expected to live with the type 2 diabetes.

This forecast illustrates the number of diabetes type 1 disease cases in the United States from 2007 to 2020. In 2020, some 500,000 adults of the U.S. population are expected to live with the type 1 diabetes.

The US diabetes devices market, a significant segment of the global market, is experiencing robust growth, driven by the rising prevalence of diabetes and an aging population. The market, valued at approximately $25.16 billion in 2025, is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.27% from 2025 to 2033. This growth is fueled by several key factors: increasing adoption of continuous glucose monitoring (CGM) systems offering improved diabetes management, technological advancements leading to smaller, more user-friendly devices, and growing awareness of the benefits of proactive diabetes care. The market is segmented into monitoring and management devices. Within monitoring, self-monitoring blood glucose (SMBG) devices, including glucometers, test strips, and lancets, remain a substantial portion, although CGM is experiencing faster growth due to its real-time data capabilities and improved patient outcomes. The management device segment is dominated by insulin delivery systems like insulin pumps, syringes, pens, and jet injectors, with insulin pumps showing particularly strong growth prospects due to their convenience and efficacy in managing insulin delivery. Competitive intensity is high, with major players like Abbott, Medtronic, Dexcom, and Novo Nordisk vying for market share through continuous innovation and strategic partnerships. The North American region, particularly the US, holds a significant market share owing to high diabetes prevalence, advanced healthcare infrastructure, and strong regulatory support for innovative medical technologies. The market's growth trajectory is expected to remain positive through 2033, although certain restraints could influence the pace. These include high costs associated with some devices, particularly CGMs and insulin pumps, creating access barriers for some patients. However, increasing insurance coverage and the development of more affordable alternatives are mitigating these challenges. Furthermore, technological advancements, such as the integration of artificial intelligence and machine learning in diabetes management, are expected to further enhance the market's potential. Companies are focusing on developing integrated systems that combine CGM with insulin delivery, providing a more holistic approach to diabetes management. This trend will likely drive further growth and consolidation within the market. Future success will depend on companies' ability to innovate, offer competitive pricing strategies, and address the evolving needs of patients. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Growing Diabetes and Obesity Population in the United States.

The crude prevalence rate of diabetes is defined as the ratio of respondents that are 18 years or older who have ever been told by a health professional that they had diabetes (other than during pregnancy) over the total number of respondents in the study (excluding those who refused to answer, had a missing answer, or answered “don’t know/not sure”).Prevalence data are derived from Behavioral Risk Factor Surveillance System (BRFSS) (numerator) and population estimates from the U.S. Census Bureau (denominator).The 500 Cities Project seeks to provide city- and census tract-level small area estimates for chronic disease risk factors, health outcomes, and clinical preventive service use for the largest 500 cities in the United States.Data source: CDC (Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion)Date: 2015

Data for cities, communities, and City of Los Angeles Council Districts were generated using a small area estimation method which combined the survey data with population benchmark data (2022 population estimates for Los Angeles County) and neighborhood characteristics data (e.g., U.S. Census Bureau, 2017-2021 American Community Survey 5-Year Estimates). This indicator is based on self-report of ever being diagnosed with diabetes (type 1 or 2).Diabetes is associated with decreased life expectancy, heart disease and stroke, lower limb amputations, kidney disease, and blindness. It is also closely linked with obesity. Cities and communities can help prevent diabetes by adopting policies that support healthy food retail and physical activity and improve access to preventive care services.For more information about the Community Health Profiles Data Initiative, please see the initiative homepage.

North America Insulin Syringe Market size was valued at USD 259 Million in 2024 and is projected to reach USD 290 Million by 2032, growing at a CAGR of 1.7% from 2025 to 2032.

Key Market Drivers:

Increasing Diabetes Prevalence: According to the Centers for Disease Control and Prevention's (CDC) 2022 National Diabetes Statistics Report, more than 37.3 million Americans (or 11.3% of the US population) have diabetes, with roughly 28.7 million diagnosed and 8.5 million undiagnosed. The number of individuals diagnosed with diabetes has more than quadrupled over the previous 20 years, resulting in a significant and rising need for insulin syringes.

Ageing Population Growth: According to the United States Census Bureau, the number of Americans aged 65 and over is expected to reach 77 million in 2034. This age change is especially relevant for the insulin syringe industry, as type 2 diabetes is more common in older persons.

In 2023, it was estimated that almost 21 percent of those aged 65 years and older in the United States had been diagnosed with diabetes. This statistic shows the percentage of U.S. adults aged 65 years and older who had ever been told by a doctor or other health professional they had diabetes from 2019 to 2023.

Age-adjusted rate of diabetes deaths by sex, race/ethnicity, age; trends if available. Source: Santa Clara County Public Health Department, VRBIS, 2007-2016. Data as of 05/26/2017; U.S. Census Bureau; 2010 Census, Tables PCT12, PCT12H, PCT12I, PCT12J, PCT12K, PCT12L, PCT12M; generated by Baath M.; using American FactFinder; Accessed June 20, 2017. METADATA:Notes (String): Lists table title, notes and sources.Year (Numeric): Year of data.Category (String): Lists the category representing the data: Santa Clara County is for total population, sex: Male and Female, race/ethnicity: African American, Asian/Pacific Islander, Latino and White (non-Hispanic White only); age categories as follows: 18 to 24, 25 to 34, 35 to 44, 45 to 54, 55 to 64, 65 to 74, 75 to 84, 85+; United States.Rate per 100,000 people (Numeric): Rate of diabetes deaths. Rates for age groups are reported as age-specific rates per 100,000 people. All other rates are age-adjusted rates per 100,000 people.

The US diabetes drugs and devices market, a significant segment of the global market, is projected to experience robust growth, exceeding a Compound Annual Growth Rate (CAGR) of 4% from 2025 to 2033. This expansion is fueled by several key factors. The rising prevalence of diabetes, particularly type 2 diabetes, among the aging US population is a primary driver. Increased awareness of diabetes management and the availability of advanced diagnostic tools, such as continuous glucose monitoring (CGM) systems, are further accelerating market growth. Technological advancements in insulin delivery systems, including the development of smart insulin pumps and improved insulin analogs, are also contributing to market expansion. Moreover, the growing preference for convenient and effective self-management options is driving the adoption of home-based testing and monitoring devices. The market is segmented into devices (monitoring and management) and drugs (oral anti-diabetes drugs, insulin, and others), with significant contributions from both segments. Leading companies such as Novo Nordisk, Medtronic, and Abbott are actively involved in developing and marketing innovative products, further fueling market competition and growth. Despite the positive outlook, the market faces certain challenges. High costs associated with diabetes treatment, including drugs and devices, pose a significant barrier for many patients. Insurance coverage limitations and the complexities of managing diabetes can hinder treatment adherence. Furthermore, the development of new and potentially more effective treatments necessitates continuous research and development investment. However, given the substantial prevalence of diabetes and the increasing focus on effective management strategies, the US diabetes drugs and devices market is poised for substantial long-term growth, presenting significant opportunities for both established players and emerging companies. The North American region, particularly the US, is expected to retain a significant market share due to its advanced healthcare infrastructure and higher disease prevalence. Recent developments include: June 2023: The initial allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells, Lantidra, has been sanctioned by the U.S. Food and Drug Administration for the management of type 1 diabetes. Lantidra is specifically authorized for adults with type 1 diabetes who are incapable of achieving target glycated hemoglobin (average blood glucose levels) due to recurrent episodes of severe hypoglycemia (low blood sugar) despite intensive diabetes management and education., January 2023: Bexagliflozin (Brenzavvy, TheracosBio) has been granted approval by the US Food and Drug Administration (FDA) for the management of type 2 diabetes in adults. This oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, taken once daily at a dosage of 20 mg, is recommended as a supplementary treatment alongside diet and exercise to enhance glycemic control specifically for individuals with type 2 diabetes, excluding those with type 1 diabetes.. Notable trends are: Continuous Glucose Monitoring Segment is Expected to Witness Highest Growth Rate Over the Forecast Period.

BackgroundThe aim of this study was to estimate the economic burden of diabetes mellitus (DM) in Iran from 2009 to 2030.MethodsA Markov micro-simulation (MM) model was developed to predict the DM population size and associated economic burden. Age- and sex-specific prevalence and incidence of diagnosed and undiagnosed DM were derived from national health surveys. A systematic review was performed to identify the cost of diabetes in Iran and the mean annual direct and indirect costs of patients with DM were estimated using a random-effect Bayesian meta-analysis. Face, internal, cross and predictive validity of the MM model were assessed by consulting an expert group, performing sensitivity analysis (SA) and comparing model results with published literature and national survey reports. Sensitivity analysis was also performed to explore the effect of uncertainty in the model.ResultsWe estimated 3.78 million cases of DM (2.74 million diagnosed and 1.04 million undiagnosed) in Iran in 2009. This number is expected to rise to 9.24 million cases (6.73 million diagnosed and 2.50 million undiagnosed) by 2030. The mean annual direct and indirect costs of patients with DM in 2009 were US$ 556 (posterior standard deviation, 221) and US$ 689 (619), respectively. Total estimated annual cost of DM was $3.64 (2009 US$) billion (including US$1.71 billion direct and US$1.93 billion indirect costs) in 2009 and is predicted to increase to $9.0 (in 2009 US$) billion (including US$4.2 billion direct and US$4.8 billion indirect costs) by 2030.ConclusionsThe economic burden of DM in Iran is predicted to increase markedly in the coming decades. Identification and implementation of effective strategies to prevent and manage DM should be considered as a public health priority.